New 'Natural Ozempic' Found in Brain

A promising new molecule, BRINP2-related peptide (BRP), has been identified by Stanford University researchers as a potential alternative to current weight-loss drugs. Naturally present in the brain, BRP specifically targets the hypothalamus, an area responsible for appetite and metabolism regulation. In studies involving obese mice and minipigs, BRP significantly reduced food intake within an hour of a single injection, with mice showing noticeable weight loss. Crucially, these animals did not experience the common side effects associated with GLP-1 medications, such as nausea or taste aversion. The researchers believe BRP's targeted action in the brain may offer a more tolerable approach compared to GLP-1 agonists, which affect multiple bodily tissues, leading to widespread effects like slowed digestion and blood sugar changes. Current GLP-1 medications see high discontinuation rates due to side effects, with many patients regaining weight. The development of BRP involved an AI algorithm scanning thousands of genes, pinpointing BRP for its effectiveness in activating a key cell proliferation gene. While further research is needed to understand its human application, the findings offer significant hope for developing more effective and safer obesity treatments.